Press Releases from SignaBlok, Inc. (2 total)
SignaBlok Achieves Key In Vivo Proof of Concept for Treatment of Cancer and Seps …
– Novel First-in-Class Peptide Inhibitor of TREM-1 Modulates the Inflammatory Response and Shows Promise for Treatment of Cancer and Sepsis –
Shrewsbury, MA, September 17, 2013…
SignaBlok Awarded DARPA Contract to Support New Technology to Combat Sepsis
Shrewsbury, MA, January 10, 2012 – SignaBlok, Inc., a Massachusetts-based emerging biopharmaceutical company, today announced that it has been awarded a contract from the Defense…
Go To Page:
